Korean J Dermatol.  2009 Apr;47(4):483-486.

A Case of Cutaneous Plasmacytoma Treated with Bortezomib and Radiotherapy

Affiliations
  • 1Department of Dermatology, School of Medicine, Kyunghee University, Seoul, Korea. mhlee@khmc.or.kr
  • 2Department of Internal Medicine, School of Medicine, Kyunghee University, Seoul, Korea.

Abstract

Multiple myeloma is a hematologic malignancy characterized by the proliferation of monoclonal plasma cells that produce monoclonal immunoglobulins. Cutaneous involvement is very uncommon in patients with multiple myeloma. It usually appears late in the course of the disease. Bortezomib is a potent proteasome inhibitor, recently introduced in the treatment of multiple myeloma. It has proven to be safe and effective in the treatment of refractory or relapsed multiple myeloma. In this study, we show the high efficacy of a concurrent therapeutic approach with bortezomib and radiation in a patient with a cutaneous plasmacytoma.

Keyword

Bortezomib; Multiple myeloma; Plasmacytoma; Radiotherapy
Full Text Links
  • KJD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr